226 related articles for article (PubMed ID: 34135137)
1. Molecular targets in GI malignancies - A pathologist's perspective.
Pawar S; Sharma A
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
[TBL] [Abstract][Full Text] [Related]
2. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.
Domagała P; Hybiak J; Sulżyc-Bielicka V; Cybulski C; Ryś J; Domagała W
Pol J Pathol; 2012 Nov; 63(3):145-64. PubMed ID: 23161231
[TBL] [Abstract][Full Text] [Related]
4. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
5. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
McIntire M; Redston M
Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
[TBL] [Abstract][Full Text] [Related]
7. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies.
Bhamidipati D; Subbiah V
Trends Cancer; 2023 Mar; 9(3):237-249. PubMed ID: 36494311
[TBL] [Abstract][Full Text] [Related]
8. [Personalized tumor therapy for gastrointestinal tumors].
Ettrich TJ; Perkhofer L; Seufferlein T
Internist (Berl); 2015 Sep; 56(9):1069-78. PubMed ID: 26148698
[TBL] [Abstract][Full Text] [Related]
9. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
[TBL] [Abstract][Full Text] [Related]
10. Cancer Targeted Therapy Strategy: The Pathologist's Perspectives.
Alessandrini L; Perin T; Kadare S; Del Pup L; Memeo L; Steffan A; Colarossi L; Berretta M; De Paoli P; Canzonieri V
Curr Cancer Drug Targets; 2018; 18(5):410-420. PubMed ID: 29189158
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for personalized medicine in GI cancers.
Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
[TBL] [Abstract][Full Text] [Related]
12. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience.
Welland S; deCastro T; Bathon M; Wirth TC; Reineke-Plaaß T; Saborowski M; Lehmann U; Saborowski A; Vogel A
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2137-2144. PubMed ID: 34436668
[TBL] [Abstract][Full Text] [Related]
14. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer.
El Dika I; Ilson DH
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1085-1092. PubMed ID: 30092682
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
16. The current state of molecular profiling in gastrointestinal malignancies.
Mukherji R; Yin C; Hameed R; Alqahtani AZ; Kulasekaran M; He AR; Weinberg BA; Marshall JL; Hartley ML; Noel MS
Biol Direct; 2022 Jun; 17(1):15. PubMed ID: 35668531
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
18. Precision Medicine in Gastrointestinal Pathology.
Wang DH; Park JY
Arch Pathol Lab Med; 2016 May; 140(5):449-60. PubMed ID: 27128302
[TBL] [Abstract][Full Text] [Related]
19. [Molecular tumor board in uro-oncology-from a pathologist's view].
Gaisa NT; Kristiansen G; Perner S
Urologe A; 2019 Jul; 58(7):747-751. PubMed ID: 31049636
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors to targeted treatment in gastrointestinal carcinomas.
Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
